cme
The synergistic treatment of heart and kidney disease
Dtsch Arztebl Int 2026; 123: 19-26. DOI: 10.3238/arztebl.m2025.0131
; ; ; ;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Universitäres Herzzentrum Basel, Universitätsspital Basel, Universität Basel, Schweiz: Prof. Dr. med. Felix Mahfoud, M.A.; Dr. med. Felix Götzinger
Cardiovascular Research Institute Basel (CRIB), University Heart Center Basel, Universität Basel, Schweiz: Prof. Dr. med. Felix Mahfoud, M.A.; Dr. med. Felix Götzinger
Klinik für Nieren und Hochdruckkrankheiten, Rheumatologische und Immunologische Erkrankungen, Uniklinik RWTH Aachen: Prof. Dr. med. Rafael Kramann
Medizinischen Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik Aachen, RWTH Aachen: Prof. Dr. med. Nikolaus Marx
Klinik für Nieren-, Hochdruck- und Autoimmunerkrankungen, Klinikum der Landeshauptstadt Stuttgart gKAöR, Katharinenhospital, Stuttgart: Prof. Dr. med. Vedat Schwenger
Cardiovascular Research Institute Basel (CRIB), University Heart Center Basel, Universität Basel, Schweiz: Prof. Dr. med. Felix Mahfoud, M.A.; Dr. med. Felix Götzinger
Klinik für Nieren und Hochdruckkrankheiten, Rheumatologische und Immunologische Erkrankungen, Uniklinik RWTH Aachen: Prof. Dr. med. Rafael Kramann
Medizinischen Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik Aachen, RWTH Aachen: Prof. Dr. med. Nikolaus Marx
Klinik für Nieren-, Hochdruck- und Autoimmunerkrankungen, Klinikum der Landeshauptstadt Stuttgart gKAöR, Katharinenhospital, Stuttgart: Prof. Dr. med. Vedat Schwenger
| 1. | Magnussen C, Ojeda FM, Leong DP, et al.: Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 2023; 389: 1273–85 CrossRef MEDLINE PubMed Central |
| 2. | Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305 CrossRef MEDLINE |
| 3. | Rossing P, Caramori ML, Chan JCN, et al.: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022; 102: S1–S127 CrossRef MEDLINE |
| 4. | Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The prevalence of renal failure—results from the German health interview and examination survey for adults, 2008–2011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85–91 CrossRef VOLLTEXT |
| 5. | Ndumele CE, Neeland IJ, Tuttle KR, et al.: A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023; 148: 1636–64 CrossRef CrossRef |
| 6. | Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al.: Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J 2024; 45: 4063–98 CrossRef MEDLINE |
| 7. | Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–67 CrossRef MEDLINE |
| 8. | Ostrominski JW, Claggett BL, Miao ZM, et al.: Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2024; 84: 223–8 CrossRef MEDLINE |
| 9. | Solomon SD, McMurray JJV, Vaduganathan M, et al.: Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024; 391: 1475–85 CrossRef MEDLINE |
| 10. | Pitt B, Pfeffer MA, Assmann SF, et al.: Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383–92 CrossRef MEDLINE |
| 11. | Solomon SD, McMurray JJV, Claggett B, et al.: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Eng J Med 2022; 387: 1089–98 CrossRef MEDLINE |
| 12. | Solomon SD, McMurray JJV, Anand IS, et al.: Angiotensin—neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609–20 CrossRef MEDLINE |
| 13. | Bundesärztekammer (BÄK) KB (KBV), A der WMF (AWMF): Nationale Versorgungsleitlinie Typ-2-Diabetes – Langfassung. AWMF 2023. https://register.awmf.org/de/leitlinien/detail/nvl-001 (last accessed on 12 September 2025). |
| 14. | Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) Deutsche Gesellschaft für Nephrologie (DGfN): Versorgung von Patient*innen mit chronischer, nicht-nierenersatztherapiepflichtiger Nierenkrankheit in der Hausarztpraxis. AWMF 2024. |
| 15. | Mancia G, Kreutz R, Brunström M, et al.: 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41: 1874–2071 CrossRef MEDLINE |
| 16. | McEvoy JW, McCarthy CP, Bruno RM, et al.: 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45: 3912–4018 CrossRef MEDLINE |
| 17. | Vaduganathan M, Docherty KF, Claggett BL, et al.: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400 (10354): 757–67 CrossRef MEDLINE |
| 18. | Zelniker TA, Wiviott SD, Raz I, et al.: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–9 CrossRef MEDLINE |
| 19. | Marx N, Federici M, Schütt K, et al.: 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043–140 CrossRef MEDLINE |
| 20. | McDonagh TA, Metra M, Adamo M, et al.: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599–726 CrossRef MEDLINE |
| 21. | McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008 CrossRef MEDLINE |
| 22. | Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–28 CrossRef MEDLINE |
| 23. | Packer M, Anker SD, Butler J, et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–24 CrossRef MEDLINE |
| 24. | Zannad F, Ferreira JP, Pocock SJ, et al.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819–29 CrossRef MEDLINE |
| 25. | Anker SD, Butler J, Filippatos G, et al.: Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–61 CrossRef MEDLINE |
| 26. | EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al.: Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117–27 CrossRef MEDLINE PubMed Central |
| 27. | Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Eng J Med 2016; 375: 323–34 CrossRef MEDLINE |
| 28. | The EMPA-KIDNEY Collaborative Group: Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 2025; 392: 777–87 CrossRef MEDLINE PubMed Central |
| 29. | Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436–46 CrossRef MEDLINE |
| 30. | McDonagh TA, Metra M, Adamo M, et al.: 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627–39 CrossRef MEDLINE |
| 31. | Ussher JR, Drucker DJ: Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023; 20: 463–74 CrossRef MEDLINE |
| 32. | Wilding JPH, Batterham RL, Calanna S, et al.: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989–1002 CrossRef MEDLINE |
| 33. | Marso SP, Bain SC, Consoli A, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med 2016; 375: 1834–44 CrossRef CrossRef MEDLINE PubMed Central |
| 34. | Husain M, Birkenfeld AL, Donsmark M, et al.: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841–51 CrossRef MEDLINE |
| 35. | Perkovic V, Tuttle KR, Rossing P, et al.: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109–21 CrossRef MEDLINE |
| 36. | Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.: Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Eng J Med 2023; 389: 1069–84 CrossRef MEDLINE |
| 37. | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes. N Eng J Med 2023; 389: 2221–32 CrossRef MEDLINE |
| 38. | Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Langfassung. https://register.awmf.org/de/leitlinien/detail/nvl-006 (last accessed on 12 Septmber 2025). |
| 39. | Pitt B, Filippatos G, Agarwal R, et al.: Cardiovascular events with finerenone in kidney disease and type 2 Diabetes. N Engl J Med 2021; 385: 2252–63 CrossRef MEDLINE |
| 40. | Neuen BL, Heerspink HJL, Vart P, et al.: Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149: 450–62 CrossRef MEDLINE |
| e1. | Ronco C, McCullough P, Anker SD, et al.: Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality Initiative. Eur Heart J 2010; 31: 703–11 CrossRef MEDLINE PubMed Central |
| e2. | Bauersachs J, Jaisser F, Toto R: Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65: 257–63 CrossRef MEDLINE |
| e3. | Dicker D, Nguyen G, Abate D, et al.: Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: A systematic analysis for the global burden of disease study 2017. Lancet 2018; 392: 1684–735 CrossRef MEDLINE |
| e4. | Murray CJL, Aravkin AY, Zheng P, et al.: Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet 2020; 396: 1223–49 CrossRef MEDLINE |
| e5. | Naghavi M, Ong KL, Aali A, et al.: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the global burden of disease study 2021. Lancet 2024; 403: 2100–32 CrossRef MEDLINE |
| e6. | Ensminger S, Thiele H, Falk V, Rudolph V: Der Deutsche Herzbericht – Update 2024 – Eine Zusammenfassung der wichtigsten Erkenntnisse. Kardiologie 2024; 18: 476–84 CrossRef |
| e7. | Zhou B, Carrillo-Larco RM, Danaei G, et al.: Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398: 957–80 CrossRef MEDLINE |
| e8. | Jadoul M, Aoun M, Masimango Imani M: The major global burden of chronic kidney disease. Lancet Glob Health 2024; 12: e342–e3 CrossRef MEDLINE |
| e9. | Chong B, Jayabaskaran J, Jauhari SM, et al.: Global burden of cardiovascular diseases: Projections from 2025 to 2050. Eur J Prev Cardiol 2024; zwae281. doi: 10.1093/eurjpc/zwae281. Online ahead of print CrossRef MEDLINE |
| e10. | Ong KL, Stafford LK, McLaughlin SA, et al.: Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the global burden of disease study 2021. Lancet 2023; 402: 203–34 CrossRef MEDLINE |
| e11. | Alla F, Zannad F, Filippatos G: Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91–5 CrossRef MEDLINE |
| e12. | Rudiger A, Harjola VP, Müller A, et al.: Acute heart failure: Clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005; 7: 662–70 CrossRef MEDLINE |
| e13. | Jackson CE, Solomon SD, Gerstein HC, et al.: Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet 2009; 374: 543–50 CrossRef MEDLINE |
| e14. | Bailey LN, Levitan EB, Judd SE, et al.: Association of urine albumin excretion with incident heart failure hospitalization in community-dwelling adults. JACC Heart Fail 2019; 7: 394–401 CrossRef MEDLINE PubMed Central |
| e15. | Sharma A, Zhao X, Hammill BG, et al.: Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Heart Fail 2018; 11: e004646 CrossRef MEDLINE |
| e16. | Streng KW, Nauta JF, Hillege HL, et al.: Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 2018; 271: 132–9 CrossRef MEDLINE |
| e17. | Stevens PE, Ahmed SB, Carrero JJ, et al.: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117–S314 CrossRef MEDLINE |
| e18. | Wu HY, Peng YS, Chiang CK, et al.: Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus. JAMA Intern Med 2014; 174: 1108 CrossRef MEDLINE |
| e19. | Schmieder RE, Schutte R, Schumacher H, et al.: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: An analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014; 57: 2019–29 CrossRef MEDLINE |
| e20. | Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–6 CrossRef MEDLINE |
| e21. | Ortiz A, Wanner C, Gansevoort R, et al.: Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association. Eur J Prev Cardiol 2022; 29: 2211–5 CrossRef MEDLINE |
| e22. | Inker LA, Eneanya ND, Coresh J, et al.: New creatinine—and cystatin C–based equations to estimate GFR without race. N Eng J Med 2021; 385: 1737–49 CrossRef MEDLINE PubMed Central |
| e23. | van der Giet M, Nitschmann S: Cystatin C-basierte Schätzung der glomerulären Filtrationsrate. Inn Med 2023; 64: 711–4 CrossRef MEDLINE |
| e24. | Manetti L, Pardini E, Genovesi M, et al.: Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28: 346–9 CrossRef MEDLINE |
| e25. | Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C: Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944–7 CrossRef MEDLINE |
| e26. | Risch L, Herklotz R, Blumberg A, Huber AR: Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47: 2055–9 CrossRef |
| e27. | George LK, Koshy SKG, Molnar MZ, et al.: Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail 2017; 10: e003825 CrossRef MEDLINE PubMed Central |
| e28. | El Chamieh C, Liabeuf S, Massy Z: Uremic toxins and cardiovascular risk in chronic kidney disease: What have we learned recently beyond the past findings? Toxins (Basel) 2022; 14: 280 CrossRef MEDLINE PubMed Central |
| e29. | Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A: Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29–36 CrossRef MEDLINE |
| e30. | Wanner C, Heerspink HJL, Zinman B, et al.: Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29: 2755–69 CrossRef MEDLINE PubMed Central |
| e31. | Neeland IJ, Ross R, Després JP, et al.: Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement. Lancet Diabetes Endocrinol 2019; 7: 715–25 CrossRef MEDLINE |
| e32. | Mahabadi AA, Massaro JM, Rosito GA, et al.: Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2008; 30: 850–6 CrossRef MEDLINE PubMed Central |
| e33. | Parati G, Esler M: The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058–66 CrossRef MEDLINE |
| e34. | SPRINT Research Group, Wright JT, Williamson JD, et al.: A randomized trial of intensive versus standard blood-pressure control. N Enl J Med 2015; 373: 2103–16 CrossRef MEDLINE PubMed Central |
| e35. | Mach F, Baigent C, Catapano AL, et al.: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–88 CrossRef MEDLINE |
| e36. | Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303–9 CrossRef MEDLINE |
| e37. | Tunnicliffe DJ, Palmer SC, Cashmore BA, et al.: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2023; 11: CD007784 CrossRef MEDLINE PubMed Central |
| e38. | Jhund PS, Solomon SD, Docherty KF, et al.: Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF. Circulation 2021; 143: 298–309 CrossRef CrossRef PubMed Central |
| e39. | Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K: SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: A systematic review and meta-analysis. Sci Rep 2023; 13: 15922 CrossRef MEDLINE PubMed Central |
| e40. | Zannad F: Aldosterone and heart failure. Eur Heart J 1995; 16 (Suppl N): 98–102 CrossRef MEDLINE |
| e41. | Götzinger F, Kunz M, Lauder L, Böhm M, Mahfoud F: New ways of mitigating aldosterone in cardiorenal disease. Eur Heart J Cardiovasc Pharmacother 2024; 10: 557–65 CrossRef MEDLINE |
| e42. | Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Eng J Med 1999; 341: 709–17 CrossRef MEDLINE |
| e43. | Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21 CrossRef MEDLINE |
| e44. | Zannad F, McMurray JJV, Krum H, et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21 CrossRef MEDLINE |
| e45. | Currie G, Taylor AHM, Fujita T, et al.: Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol 2016; 17: 127 CrossRef MEDLINE PubMed Central |
| e46. | Charytan DM, Himmelfarb J, Ikizler TA, et al.: Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): A randomized, placebo-controlled, multiple dosage trial. Kidney Int 2019; 95: 973–82 CrossRef MEDLINE PubMed Central |
| e47. | Matsumoto Y, Mori Y, Kageyama S, et al.: Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528–36 CrossRef MEDLINE |
| e48. | Hammer F, Malzahn U, Donhauser J, et al.: A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 2019; 95: 983–91 CrossRef MEDLINE |
| e49. | Ingelfinger JR, Rosen CJ: Finerenone—halting relative hyperaldosteronism in chronic kidney disease. N Eng J Med 2020; 383: 2285–6 CrossRef MEDLINE |
| e50. | Bakris GL, Agarwal R, Anker SD, et al.: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219–29 CrossRef MEDLINE |
| e51. | Filippatos G, Anker SD, Agarwal R, et al.: Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 2021; 143: 540–52 CrossRef MEDLINE PubMed Central |
| e52. | Tamargo J, Kjeldsen KP, Delpón E, et al.: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2022; 8: 406–19 CrossRef MEDLINE |
| e53. | Bramlage P, Sims H, Minguet J, Ferrero C: The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol 2017; 24: 297–310 CrossRef MEDLINE |